WEBULL

How Raymond James’ Upgrade and 2025 Earnings Date Could Shape Stryker’s (SYK) Investment Narrative

Simply Wall St · 01/07 17:40
  • Stryker recently announced it will report its fourth-quarter and full-year 2025 results on January 29, 2026, alongside a webcast discussion of the figures.
  • This update comes as Stryker’s medical technologies reach over 150 million patients annually and analysts highlight its multi-year track record of organic revenue and earnings growth.
  • We’ll now examine how Raymond James’s upgrade, grounded in Stryker’s consistent organic growth and market share gains, could influence its investment narrative.

Rare earth metals are the new gold rush. Find out which 39 stocks are leading the charge.

Stryker Investment Narrative Recap

To own Stryker, you need to believe its broad medical technology portfolio, innovation in areas like robotics, and large patient reach can keep supporting steady organic growth despite regulatory, pricing, and cost headwinds. The upcoming January 29, 2026 earnings release and webcast are likely the key short term catalyst, while margin pressure from tariffs and higher spending, combined with a relatively full valuation, remain the most immediate risks; the Raymond James upgrade does not materially change these.

Among recent developments, the Raymond James upgrade to “Outperform,” citing five straight years of double digit organic revenue growth and market share gains, is most relevant. It has already triggered a positive share price reaction and sharpens attention on whether the forthcoming results and guidance can support Stryker’s growth narrative, especially as investors weigh regulatory delays in Europe and the impact of sustained cost pressures on profitability.

Yet behind the growth story, investors should also be aware of how prolonged EU MDR approvals and rising tariff costs could...

Read the full narrative on Stryker (it's free!)

Stryker's narrative projects $30.4 billion revenue and $5.4 billion earnings by 2028. This requires 8.4% yearly revenue growth and roughly an $2.5 billion earnings increase from $2.9 billion today.

Uncover how Stryker's forecasts yield a $427.66 fair value, a 17% upside to its current price.

Exploring Other Perspectives

SYK 1-Year Stock Price Chart
SYK 1-Year Stock Price Chart

Six fair value estimates from the Simply Wall St Community span roughly US$298 to US$428 per share, underscoring how far opinions can diverge. Against that spread, Stryker’s reliance on continued international expansion amid EU MDR approval delays could have a meaningful impact on how you think about its future performance, so it is worth comparing several of these viewpoints before deciding how it fits in your portfolio.

Explore 6 other fair value estimates on Stryker - why the stock might be worth as much as 17% more than the current price!

Build Your Own Stryker Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

No Opportunity In Stryker?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.